Download biomedica product listResearchers have identified the c-terminal fragment of the phosphate regulating hormone FGF23 (cFGF23) to better predict the risk of graft loss in kidney transplant recipients (KTRs) than its biologically active form (intact FGF23). The prospective observational cohort study included 562 maintenance KTRs with a median follow-up of 4 years.
C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival. Chu C et al.,BMC Nephrology (2021) 22:125.
FGF23 (intact) and FGF23 (C-terminal) can reliably be measured by ELISA
√ CE-marked – for IVD use in the EU
√ CORRELATE with existing ELISA methods
√ Excellent stability in all matrices
√ For plasma & serum
√ HIGH QUALITY – fully validated according to international guidelines (ICH/FDA/EMEA)
The proinflammatory cytokine Angiopoietin-2 plays a key role in endothelial cell disruption and associated events. A recent study demonstrates that a three day change in Angiopoeitin-2 levels predicts the clinical course in hospital-mortality of patients with SARS-CoV-2. Angiopoietin-2 is a relevant part of disease pathogenesis and could be a target for new specific treatments in these patients.
Read more: Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with … Villa E et al., Blood Adv. 2021 Feb 9;5(3):662-673.
Angiopoietin-2 (ANG-2) can reliably be measured by ELISA in human serum, plasma and urine samples with Biomedica’s fully validated assay kit. Only 20 µl of sample volume is required! The kit incorporates ready to use standards and controls. The assay range is optimized for clinical samples- no sample dilution required!
Features & Benefits
√ Immediate results: no sample dilution required
√ Full validation package – the assay is optimized for clinical samples
√ Kit includes ready to use standards and controls
√ Automatable
√ HIGH QUALITY GUARANTEED – https://buff.ly/3etWGHH
Find out more: Angiopoietin-2 ELISA
Extracellular vesicles (EVs) are cell-derived membranous structures that contain lipids, proteins, and nucleic acids of the source cell. They are released into the extracellular space and act as intercellular communicators. Receptor activator of NF-κB ligand RANKLL) and its receptor RANK are bone-cell derived key proteins that are crucial in regulating bone remodeling. EVs containing RANKL and RANK have recently been identified as intercellular regulators in bone biology and are attractive as drug targets and as biomarkers.
Read more Free soluble RANKL can reliably be measured by ELISA in serum and plasma.
Assay Highlights
• High sensitivity – measurable concentrations in healthy subjects
• Only ELISA that measures free, uncomplexed soluble RANKL
• CE marked – widely cited in clinical studies
Acute kidney injury (AKI) is an abrupt loss of kidney function and is independently associated with high mortality in critically ill patients. Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is expressed during the progression of renal fibrosis. A team of researchers recently demonstrated that serial measurement of plasma endostatin has useful predictive value for 30-day mortality in AKI patients.
Read more: Prognostic value of dynamic plasma endostatin for the prediction of mortality in acute kidney injury: A prospective cohort study. Jia HM et al., J Int Med Res. 2020 48(7):300060520940856. Full text
Endostatin can reliably be measured by ELISA in human serum, plasma and urine samples. Only 20 µl of sample volume is required!
Endostatin ELISA Assay Highlights: https://www.bmgrp.com/product/cardiovascular/human-endostatin-elisa-biomedica/
• SPECIFIC – no cross-reactivity with COL15A1
• CONVENIENT – Assay range optimized for clinical samples
• RELIABLE – Validated according to international quality guidelines
• EASY – Results in 4,5 h, all reagents included
Osteoporosis is the most common bone disease and its prevalence increases with age affecting approximately 200 million people worldwide. Most osteoporosis therapies aim at inhibiting bone resorption, while only a few are capable of actively promoting the generation of new bone tissue. Osteoporosis treatment with anti-Sclerostin antibodies is an newer osteo-anabolic therapy that stimulates bone formation and inhibits at the same time bone resorption. This recent review by Rauner M. and colleagues highlights the advances in the application of this newer drug in the treatment of osteoporosis and other bone diseases.
Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application. Rauner M, Taipaleenmäki H, Tsourdi E, Winter EM. Journal of Clinical Medicine. 2021; 10(4):787. https://lnkd.in/eyU3kPN
Biomedica´s Sclerostin ELISA kit https://buff.ly/2N4iVsK
• The internationally most referenced Sclerostin ELISA!
• Rigorously validated according to FDA/ICH/EMEA guidelines
• Low sample volume
High expression of leucine-rich alpha-2-glycoprotein (LRG) is closely related to angiogenesis, which may play an important role in promoting invasion and metastasis. In a retrospective study in 330 cases of early breast cancer, researchers have identified the use of LRG as a potential prognosis biomarker for early breast cancer analysis. LRG expression was associated with the tumor stage and lymphatic metastasis, and high LRG expression predicted poor survival. Analysis of serum samples from the patients may further assist in verifying the findings of this report.
Prognostic Value of LRG1 in Breast Cancer: A Retrospective Study. Zhang YS et al., 2021. Oncol Res Treat 44(1-2):36-42.
LRG can reliably be measured by ELISA in human serum, plasma and urine samples with a fully validated assay. Only 5 µl of sample volume is required!
LRG ELISA Assay Highlights https://buff.ly/31vlD26 :
• SPECIFIC – Characterized, epitope mapped antibodies
• CONVENIENT – Assay range optimized for clinical samples
• RELIABLE – Rigorously validated according to FDA/EMEA/ICH guidelines
• EASY -Results in 3 h, all reagents included
Leucine-rich alpha-2-glycoprotein (LRG) ELISA | BI-LRG
Osteoprotegerin (OPG) is a secreted protein that affects bone turnover and is implicated in heart and kidney disease. A recent study identifies OPG as an independent risk factor for all-cause mortality in patients after kidney transplantation. 982 prevalent kidney transplant (KT) recipients were followed up for all-cause mortality for 6 years. The researchers observed that each 1 pmol/L higher-serum OPG level was associated with a 49% higher risk of mortality.
Biomedica´s OPG ELISA was used in this recent study and is part of our Clinical Nephrology Biomarker ELISA line of reliable and widely cited assays.
Check out the Biomedica OPG ELISA:
CE marked
Reliable – validated according to international guidelines
Most referenced human OPG ELISA
Only 20µl sample volume required
Association between serum osteoprotegerin level and mortality in kidney transplant recipients. Gupta V et al., 2021. Transpl Int 19. doi: 10.1111/tri.13847. Epub ahead of print. PMID: 33606319
Big Endothelin-1 (Big ET-1) is a valuable tool for risk stratification in patients with cardiomyopathy
Big Endothelin-1 (Big ET-1) is a protein that is mainly produced by vascular endothelial and smooth muscle cells and cardiomyocytes. Big ET-1 has been identified as a risk factor for a poor prognosis in patients with atrial fibrillation or coronary artery disease. This current study revealed that plasma Big ET-1 is a valuable tool for risk stratification in patients with LVNC.
Big ET-1 useful for risk stratification in cardiomyopathy
Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy. Fan P et al., 2020. Heart. 2020.
Biomedica Big-ET-1 ELISA kit highlights (BI-20082H)
√ Direct measurement
√ Fully validated according to international guidelines
√ Published cut-off values
√ cited in +70 publications
CITATIONS with the Biomedica Big Endothelin-1 (Big ET-1) ELISA, cat. no. BI-20082W
Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy. Fan P, Zhang Y, Lu YT, Yang KQ, Lu PP, Zhang QY, Luo F, Lin YH, Zhou XL, Tian T. Heart. 2021 May;107(10):836-841. doi: 10.1136/heartjnl-2020-317059. Epub 2020 Oct 14. PMID: 33055147; PMCID: PMC8077223.
Abstract
Objective: To determine the prognostic role of big endothelin-1 (ET-1) in left ventricular non-compaction cardiomyopathy (LVNC).
Methods: We prospectively enrolled patients whose LVNC was diagnosed by cardiac MRI and who had big ET-1 data available. Primary end point was a composite of all-cause mortality, heart transplantation, sustained ventricular tachycardia/fibrillation and implanted cardioverter defibrillator discharge. Secondary end point was cardiac death or heart transplantation.
Results: Altogether, 203 patients (median age 44 years; 70.9% male) were divided into high-level (≥0.42 pmol/L) and low-level (<0.42 pmol/L) big ET-1 groups according to the median value of plasma big ET-1 levels. Ln big ET-1 was positively associated with Ln N-terminal pro-brain natriuretic peptide, left ventricular diameter, but negatively related to age and Ln left ventricular ejection fraction. Median follow-up was 1.9 years (IQR 0.9-3.1 years). Kaplan-Meier analysis showed that, compared with patients with low levels of big ET-1, those with high levels were at greater risk for meeting both primary (p<0.001) and secondary (p<0.001) end points. The C-statistic estimation of Ln big ET-1 for predicting the primary outcome was 0.755 (95% CI 0.685 to 0.824, p<0.001). After adjusting for confounding factors, Ln big ET-1 was identified as an independent predictor of the composite primary outcome (HR 1.83, 95% CI 1.27 to 2.62, p=0.001) and secondary outcome (HR 1.93, 95% CI 1.32 to 2.83, p=0.001).
Plasma Big Endothelin-1 Level Predicted 5-Year Major Adverse Cardiovascular Events in Patients With Coronary Artery Ectasia. Cai Z, Wang H, Yuan S, Yin D, Song W, Dou K.Front Cardiovasc Med. 2021 Nov 29;8:768431. doi: 10.3389/fcvm.2021.768431. PMID: 34912865; PMCID: PMC8667227.
Abstract
Background: Coronary artery ectasia (CAE) is found in about 1% of coronary angiography and is associated with poor clinical outcomes. The prognostic value of plasma big Endothelin-1 (ET-1) in CAE remains unknown. Methods: Patients with angiographically confirmed CAE from 2009 to 2015, who had big ET-1 data available were included. The primary outcome was 5-year major adverse cardiovascular events (MACE), defined as a component of cardiovascular death and non-fatal myocardial infarction (MI). Patients were divided into high or low big ET-1 groups using a cut-off value of 0.58 pmol/L, according to the receiver operating characteristic curve. Kaplan-Meier method, propensity score method, and Cox regression were used to assess the clinical outcomes in the 2 groups. Results: A total of 992 patients were included, with 260 in the high big ET-1 group and 732 in the low big ET-1 group. At 5-year follow-up, 57 MACEs were observed. Kaplan-Meier analysis and univariable Cox regression showed that patients with high big ET-1 levels were at increased risk of MACE (9.87 vs. 4.50%; HR 2.23, 95% CI 1.32-3.78, P = 0.003), cardiovascular death (4.01 vs. 1.69%; HR 2.37, 95% CI 1.02-5.48, P = 0.044), and non-fatal MI (6.09 vs. 2.84%; HR 2.17, 95% CI 1.11-4.24, P = 0.023). A higher risk of MACE in the high big ET-1 group was consistent in the propensity score matched cohort and propensity score weighted analysis. In multivariable analysis, a high plasma big ET-1 level was still an independent predictor of MACE (HR 1.82, 95% CI 1.02-3.25, P = 0.043). A combination of high plasma big ET-1 concentrate and diffuse dilation, when used to predict 5-year MACE risk, yielded a C-statistic of 0.67 (95% CI 0.59-0.74). Conclusion: Among patients with CAE, high plasma big ET-1 level was associated with increased risk of MACE, a finding that could improve risk stratification.
Today’s bulletin highlights a recent study investigating the association between bone quality, bone turnover, and anemia in a population-based study cohort. As FGF23 could be a link between the pathogenesis of anemia and osteoporosis, the researchers tested the hypothesis that FGF23 levels associate with hemoglobin levels and with bone quality.
Read more:
Interactions of Anemia, FGF-23, and Bone in Healthy Adults-Results From the Study of Health in Pomerania (SHIP). Hannemann A et al., J Clin Endocrinol Metab, 2021, Jan 1;106(1):e288-e299.
FGF23 (intact) and FGF23 (C-terminal) can reliably be measured by ELISA
√ CE-marked – for IVD use in the EU
√ CORRELATE with existing ELISA methods
√ Excellent stability in all matrices
√ For plasma & serum
√ HIGH QUALITY – fully validated according to international guidelines (ICH/FDA/EMEA)
February is “Heart Month” raising awareness of cardiovascular health. Cardiovascular diseases are the number 1 cause of death around the world. Preventative measures and better healthcare can reduce the risk and the burden of heart disease.
Biomedica offers a range of cardiac biomarker ELISA kits https://buff.ly/3aOoZC9 for the accurate measurement of NT-proBNP, NT-proANP, Big-Endothelin-1.
Assay Highlights:
• CE-marked for IVD use in EU
• Fully validated according to international quality guidelines
• Ready to use kits: human serum based calibrators and controls include
Fibroblast growth factor 23 (FGF23) is a protein produced by bone and is an important regulator of phosphate homeostasis. Bone impairment seen in disorders of FGF23 expression include hypophosphatemic rickets, tumoral-induced osteomalacia, and chronic kidney disease. In a study by Bilha SC et al., the researchers investigated the relationship between FGF23 and bone mass parameters in the general population, according to age, sex, menopausal, and nutritional status. FGF23 was found to be an independent predictor for bone mineral density in postmenopausal women, but was not a fine discriminator between normal bone mass and osteopenia/osteoporosis. The mechanism through which FGF23 acts upon the bone seems independent of the nutritional status, requiring further investigation. https://buff.ly/2NMb2eP
FGF23 can reliably measured by ELISA. Check out the Biomedica human FGF23 (C-terminal) and human FGF23 (intact) kits: https://buff.ly/37sunK0
• For serum and plasma samples
• Extensively validated according to international quality guidelines (FDA/ICH/EMEA)
• CE marked – for IVD use in the EU
• Plasma based standards and controls included
• Excellent correlation with existing methods
The glycoprotein Sclerostin is mainly secreted by osteocytes and acts as a negative regulator of bone mass and strength by inhibiting bone formation. Studies have shown that high intensity exercise induces an increase in serum Sclerostin levels suggesting that it may be a key protein involved in muscle and bone interaction.
A recent study by Śliwicka E and colleagues https://buff.ly/3qx6V4U evaluated the effects of a marathon race on selected myokines and Sclerostin in male recreational runners. Results show that in response to the marathon run, a complex network of endocrine interactions is initiated. Further research is needed to fully elucidate the long-term impact of prolonged high intensity exercise on the human body.
Exercise-induced increase in sclerostin- related finding: https://buff.ly/3atiBA4
Check out the Biomedica Sclerostin ELISA kit https://buff.ly/2N4iVsK
• The internationally most referenced Sclerostin ELISA!
• Rigorously validated according to FDA/ICH/EMEA guidelines
• Low sample volume
Become a Life Science Reviewer on Biocompare and receive an Amazon.com Gift Card from Biocompare now!
You have used Biomedica products? Leave your review of the product on Biocompare and help your fellow researchers with valuable new insight for making better-informed decisions, as well as tips and ideas for optimizing troubleshooting existing protocols.
Start your review here: https://buff.ly/2UbmvFU
Check out the latest two Biocompare reviews for Biomedica Products by Diego Celdran and Lisha Joshi:
NT-proANP ELISA, BI-20892: https://buff.ly/3b8fXyM
EZ4U Cell Proliferation and Cytotoxicity Assay, BI-5000: https://buff.ly/3pwa83c
The study by Kerschan-Schindl et al. proved the osteomiR™ panel to be a set of 19 emerging bone biomarkers, which together can be used as a fingerprint for osteoporosis based on the WHO criteria.
“Diagnostic Performance of a Panel of miRNAs (OsteomiR™) for Osteoporosis in a Cohort of Postmenopausal Women.”
Kerschan-Schindl K., Hackl M., Boschitsch E et al. Calcified Tissue International. 2021-01-11. doi:10.1007/s00223-020-00802-3. Click link for full text publication.
In the special issue on miRNAs in Bone Research Grillari et al. summarize the technical challenges associated with circulating miRNA research in bone health and disease.
“Circulating miRNAs in bone health and disease”
Grillari J, Mäkitie ER, Kocijan R et al. Bone Volume 145, April 2021, 115787. doi.org/10.1016/j.bone.2020.115787. Click link for full review (access until March 9, 2021).
Biological mechanisms will be further investigated within the Marie-Curie ITN project FIDELIO. Click link for more information on FIDELIO.
Link to product details:
osteomiR™ – miRNA Biomarkers, cat.no. TW-KT-011-OT
Studies show that Angiopoietin-2 is a strong predictor in patients with SARS-CoV-2
Two research teams find that increased levels of the proinflammatory cytokine Angiopoietin-2 is crucial to predict transfer to the intensive care units and is responsible for hypercoagulation observed in critically ill patients infected with SARS-CoV-2.
Studies:
Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of … patients. Smadja DM et al., Angiogenesis, 2020;1-10. Full text
Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill … patients. Hultstrom M et al., MedRxiv preprint server, 2021. Full text
SARS-CoV-2 infection has a diverse range of symptoms and may cause severe illness, in particular in patients with cardiovascular risk factors (1).
The infection is associated with an increase in procoagulant factors that have been shown to be associated with a higher mortality in patients with SARS-CoV-2 pneumonia (2). Pulmonary embolism and microvascular thrombosis in the lungs have been described in several reports in acute respiratory distress syndrome as well as in patients infected with SARS-CoV-2 (3).
Endothelial damage and inflammation in SARS-CoV-2 infection
The inflammatory cytokine storm occurring in patients infected with SARS-CoV-2, leads to the recruitment of leukocytes which damage the capillary endothelium. The disruption of the thromboprotective effect of endothelial cells likely leads to microvascular thrombosis. Thus, the endothelial damage and inflammation in several organs in patients with SARS-CoV-2 infection is a direct consequence of viral involvement and of the host inflammatory response (4).
Despite the routine thrombosis prophylaxis as standard of care treatment, the major complication in patients infected with SARS-CoV-2 is the hyperactivation of the coagulation system indicating a poor prognosis among these patients in intensive care (5).
Angiopoietin-2 (ANG2) is a soluble marker of endothelial activation
Angiopoietin-2 is a soluble protein that is involved in the regulation of vascular integrity, quiescence, and inflammation (6). ANG2 contributes to the formation of new vasculature. During angiogenesis, ANG2 exerts its effects via the angiopoietin-1/TIE2 receptor signaling system on endothelial cells. Disruption of this signaling leads to the loss of endothelial integrity. In consequence, the endothelium responds to various pro-inflammatory cytokines and growth factors.
Thus, Angiopoietin-2 is a soluble marker of endothelial activation and is involved in hemostasis, thrombo-inflammatory events or sepsis (7, 8).
ANG2 is a crucial factor to predict transfer to the intensive care unit
ANG2 induces inflammation and vascular hyperpermeability and correlates with adverse outcomes in several critical care syndromes (9). In patients infected with SARS-CoV-2, ANG2 was recently reported by Smadja and colleagues to be a relevant factor to predict transfer to the intensive care unit as it was associated with poor lung compliance (7). Thus, showing that endothelial activation reinforces the hypothesis of an infection-associated microvascular dysfunction.
Angiopoietin-2 inhibits anticoagulation in critically ill patients infected with SARS-CoV-2
Based on the above findings, Hulstrom and colleagues investigated if the highly elevated inflammatory cytokine ANG2 levels observed in SARS-CoV-2 patients had a direct effect on the coagulation system (10). Animal models and in vitro assays were included in their investigation. As thrombomodulin is expressed on the surface of endothelial cells where it binds thrombin and inhibits the intrinsic coagulation process, the scientists observed that ANG2 inhibits thrombomodulin-mediated anticoagulation and activation of protein C in human donor plasma. Furthermore, the increased ANG2 levels in patients infected with SARS-CoV-2 correlated with disease severity, hypercoagulation, and mortality by promoting hypercoagulation.
Revealing this novel mechanism for ANGPT2 in hypercoagulation the scientists suggest that inhibition of Angiopoietin-2 may be tested for treating severe cases of SARS-CoV-2 infection, as well as in certain other conditions, including sepsis (10).
Biomedica Angiopoietin-2 ELISA, Cat.No.BI-ANG2
Did you know?
Angiopoietin-2 (ANG-2) can reliably be measured by ELISA in human serum, plasma and urine samples with Biomedica’s fully validated assay kit. Only 20 µl of sample volume is required! The kit incorporates characterized epitope mapped antibodies and ready to use standards and controls. The assay range is optimized for clinical samples- no sample dilution required!
Features & Benefits
√ CONVENIENT – Assay range optimized for clinical samples;
– Ready to use standards and 2 controls included
√ RELIABLE – Rigorously validated according to FDA/EMEA/ICH guidelines
√ SPECIFIC – Characterized, epitope mapped capture and detection antibodies
√ QUALIFIED CUSTOMER SERVICE – supports you every step of the way
√ HIGH QUALITY GUARANTEED – https://www.bmgrp.com/quality
The Angiopoietin–2 ELISA kit was developed and manufactured by
Biomedica Medizinprodukte GmbH
Divischgasse 4, 1210 Wien, Austria
Tel. +43/1/291 07 45
Literature:
- Clinical course and risk factors for mortality of adult inpatients with … in Wuhan, China: a retrospective cohort study. Zhou F et al., Lancet, 2020; 395(10229):1054-1062. https://pubmed.ncbi.nlm.nih.gov/32171076/ PMID: 32171076
- Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Tang N et al., J Thromb Haemost, 2020; 18(4): 844-847. https://pubmed.ncbi.nlm.nih.gov/32073213/ PMID: 32073213
- Pulmonary embolism in … patients: awareness of an increased prevalence. Poissy J et al, Circulation, 2020; 14; 142(2):184-186. https://pubmed.ncbi.nlm.nih.gov/32330083/ PMID: 32330083
- Endotheliitis in …. Varga S. Der Pathologe, 2020; 41(Suppl 2):99-102. https://pubmed.ncbi.nlm.nih.gov/33306138/ PMID: 33306138
- … and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Al-Samkari H et al., Blood, 2020:136, 489-500. https://pubmed.ncbi.nlm.nih.gov/32492712/ PMID: 32492712
- Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology. Akwii RG et al., Cells, 2019; 8(5): 471. https://pubmed.ncbi.nlm.nih.gov/31108880/ PMID: 31108880
- Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of … patients. Smadja DM et al., Angiogenesis, 2020;1-10. https://pubmed.ncbi.nlm.nih.gov/32458111/ PMID: 32458111
- Angiopoietin 2 levels in the risk stratification and mortality outcome prediction of sepsis-associated coagulopathy. Statz S et al., Clin Appl Thromb Hemost 24(8):1223–1233. https://pubmed.ncbi.nlm.nih.gov/29996658/ PMID: 29996658
- Circulating angiopoietin-2 and the risk of mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis of 10 prospective cohort studies. Li F et al., Therapeutic advances in respiratory disease, 2020; 14, 1753466620905274 (2020). https://pubmed.ncbi.nlm.nih.gov/32043429/ PMID: 32043429
- Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill … patients. Hultstrom M et al., MedRxiv preprint server, 2021. https://www.medrxiv.org/content/10.1101/2021.01.13.21249429v1.full
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a global health problem. At present, prior exposure to Mtb can be determined by blood-based interferon-gamma release assay (IGRA), but active TB is not always detectable by blood tests.
Leucine-rich alpha-2 glycoprotein (LRG), a new inflammatory biomarker, and has been shown that it could be a promising biomarker when performed following IGRA for the detection of active TB.
Learn more: https://www.nature.com/articles/s41598-020-60450-3
Did you know?
LRG can reliably be measured by ELISA in human serum, plasma and urine samples with Biomedica’s fully validated assay kit. https://www.bmgrp.com/product/cardiovascular/leucine-rich-alpha-2-glycoprotein-lrg-elisa-bi-lrg/
√ CONVENIENT – Assay range optimized for clinical samples;
– Ready to use standards and 2 controls included
√ RELIABLE – Rigorously validated according to FDA/EMEA/ICH guidelines
√ SPECIFIC – Characterized, epitope mapped capture and detection antibodies
√ QUALIFIED CUSTOMER SERVICE – supports you every step of the way
√ HIGH QUALITY GUARANTEED
Biomedica’s Sclerostin ELISA:
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA guidelines
√ LOW SAMPLE VOLUME – only 20 µl sample / well
√ EASY – convenient ready to use protocol
√ MOST REFERENCED
Also available: Bioactive Sclerostin ELISA
√ specific antibodies targeting the receptor binging region
Complete ready to use ELISA kits for superior performance and reproducibility.
Related ELISAs: free soluble RANKL, OPG, DKK-1, FGF23 – Analytical Service Measurements
Planning your study? Contact us by e-mail or phone to receive your special study quote.
Myocardial infarction leads to a an increase in serum levels of ANP (Atrial natriuretic peptide). In a study with a myocardial infarction rat animal model, Zhang et al. showed that the increase in ANP occurs primarily due to an AGTR1/NF-κB mediated upregulation of the ANP gene transcription in the infarcted myocardium. This suggests that specifically the infarcted zone is an important pharmacological target for routine medical heart failure therapies that target AGTR1. https://buff.ly/3ix5tfs
Check out the Biomedica NT-proANP ELISA https://buff.ly/3kCJc0I :
• CE marked – for IVD use in the EU
• Small sample volume – 10 µl / well
• Assay suitable for rat/mouse samples – NT-proANP as a cardiovascular safety biomarker in rats
Mayi BS et al., PLoS Pathog; 2021, Jan 4;17(1):e1009153. Full text review
Summary of the findings please click here
Did you know?
Total soluble Neuropilin-1 can easily be measured in serum, plasma and other biological fluids
√ Only assay that measures free and ligand bound soluble NRP1
√ Low sample volume – only 10µl needed
√ Highly specific using epitope mapped antibodies
√ Rigorously validated according to international guidelines
Related publications:
Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. Cantuti-Castelvetri L et al., Science 13 Nov, 2020; Vol. 370, Issue 6518, pp. 856-860. Full publication
Neuropilin-1 is a host factor for SARS-CoV-2 infection. Daly JL et al., Science, 13 Nov 2020; Vol. 370, Issue 6518, pp. 861-865. Full publication
Acute declines in kidney #function occur in approximately 20%-30% of patients with acute decompensated heart failure, but its significance is unclear, and the importance of its context is not known.
In a study by McCallum et al., a decline in estimated glomerular filtration rate (eGFR), related to worsening kidney function, was not significantly associated with death and rehospitalization of the patient. However, there is a remarkable interaction between decline in eGFR and change in NT-proBNP. When both eGFR and NT-proBNP declined, acute decompensated heart failure patients had significantly better outcomes.
This suggests that including of congestion biomarkers may aid clinical interpretation of eGFR declines.
https://www.sciencedirect.com/science/article/pii/S0002934319305297#.
Why NT-proBNP ELISA from Biomedica?
√ FLEXIBLE and independent solution – can be run in every lab
√ SPECIFIC for NT-proBNP (1-76)
√ RELIABLE and REPRODUCIBLE results
√ GOOD CORRELATION with existing methods
https://www.bmgrp.com/product/cardiovascular/nt-probnp-elisa-biomedica/
Rafiou Agoro, Pu Ni, Megan L. Noonan, and Kenneth E. White. Front Endocrinol (Lausanne). 2020; 11: 592.
Full publication https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485387/
FGF23 is a phosphaturic hormone derived and secreted primarily by bone osteocytes. Mature, bioactive FGF23 is physiologically designed to target the kidney to regulate phosphate and vitamin D homeostasis; and, in a feedback mechanism to control bone mineralization and FGF23 production.
This review explores the signals involved in the positive and negative regulation of FGF23 in osteocytes, and bridges bone responses with the review of current knowledge on FGF23 endocrine functions in the kidneys.
Check out the Biomedica human FGF23 (C-terminal) and human FGF23 (intact) ELISA kits: https://www.bmgrp.com/shop?category=&type=&reactivity=&s=fgf
- For serum and plasma samples
- Extensively validated according to FDA/ICH/EMEA guidelines
- CE marked – for IVD use in the EU
- Excellent correlation with existing methods
Vascular Endothelial Growth Factor (VEGF) induces angiogenesis, but also disrupts vascular barrier function in diseased tissues. VEGF-mediated pathogenic effects are due to its effects on vascular permeability, resulting in injury to ischemic tissues after stroke or myocardial infarction. In cancer, VEGF-mediated disruption of the vascular barrier may lead to metastatic disease.
Check out our new high quality human VEGF ELISA – developed and manufactured by Biomedica:
Highlights:
√ SMALL SAMPLE VOLUME: only 10µl sample / well required
√ HIGH SENSITIVITY: measurable values in both serum and plasma
√ RELIABLE: rigorously validated according to FDA/ICH/EMEA guidelines
√ EASY: ready to use calibrators & controls included
√ EXCELLENT: correlates with existing methods
√ DAY TEST: results in 4.5 h
Literature:
Review: VEGF in Signaling and Disease: Beyond Discovery and Development. Apte RS et al., Cell. 2019; 176, 6: 1248–64.
e-Poster: “Highly sensitive quantification of human VEGF with an ELISA”
Neuropilin-1 (NRP1) is abundantly expressed in the respiratory and olfactory epithelium, with highest expression in endothelial cells and in the epithelial cells facing the nasal cavity. Neuropathological analysis of human COVID-19 autopsies revealed SARS-CoV-2 infected NRP1-positive cells in the olfactory epithelium and bulb. Link to abstract.
NRP1 can reliably be measured by ELISA in human serum, plasma and urine samples with a fully validated assay. Only 10 µl of sample volume is required!
Total NRP1 ELISA Assay Highlights:
- Only assay that detects free and ligand-bound soluble NRP1
- SPECIFIC – Characterized, epitope mapped antibodies
- CONVENIENT – Assay range optimized for clinical samples
- RELIABLE – Rigorously validated according to FDA/EMEA/ICH guidelines
- APPLICATION for Human and Non-Human Samples
Find out more: Total Neuropilin-1 ELISA
Related publications:
Neuropilin‑1 as a new potential SARS‑CoV‑2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID‑19 . https://www.spandidos-publications.com/10.3892/mmr.2020.11510.
Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. https://www.biorxiv.org/content/10.1101/2020.06.07.137802v1.abstract .
Fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) are regulators of renal phosphate excretion and vitamin D metabolism.
In chronic kidney disease, circulating FGF23 and PTH concentrations progressively increase as renal function declines. Oxidation of PTH at two methionine residues (positions 8 and 18) causes a loss of PTH function. However, the impact of non-oxidized PTH and oxidized PTH on FGF23 synthesis and how n‐oxPTH and oxPTH concentrations are affected by CKD, is yet unknown.
Research by Zeng et al. now shows that only non-oxidized PTH correlates with increased FGF23 synthesis in CKD. Simultaneously, ox-PTH and intact PTH concentrations increase more substantially than n-ox-PTH. This highlights the importance of different PTH derivatives.
Learn more about Biomedica’s C-terminal & intact FGF23 Assays
CE-marked
Extensively validated according to FDA/ICH/EMEA guidelines
Ngaio Diagnostics reached out to Biomedica due to a request from one of their customers. After speaking to some of his key customers it was clear for Stuart McKenzie, Managing Director of Ngaio Diagnostics, that “Biomedica’s unique kit range and great reputation for excellent kits” were a perfect fit to Ngaio’s current distribution portfolio.
For Biomedica “Ngaio is the right partner and well placed to market Biomedica’s biomarker ELISAs to the research & clinical market on the other side of the world.”
Ngaio Diagnostics is a privately owned laboratory supply company based in Nelson, New Zealand. Established in 1991, we specialise in the distribution and support of quality products to hospital laboratories, community clinical laboratories, veterinary laboratories, veterinary practices, food testing & environmental laboratories and food processors. https://bit.ly/2SzEST2
Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis. Sclerostin, a glycoprotein secreted mainly by osteocytes, regulates bone mass by decreasing bone formation.
In patients with hepatic cirrhosis, areal bone mineral density (aBMD) is decreased especially at the lumbar spine. aBMD alone can be insufficient to explain increased fracture risk and bone microarchitecture can provide additional information. However, since assessment of bone microarchitecture is complex, biomarkers could help assess fracture risk. In a study of several biomarkers, Wakolbinger et al. found a correlation between sclerostin and altered bone microarchitecture in hepatic cirrhosis https://link.springer.com/article/10.1007/s00508-019-01595-8.
Biomedica´s bioactive sclerostin ELISA measures bioactive sclerostin by using a monoclonal antibody directed at the LRP5/6 binding region, capturing all circulating sclerostin forms containing the free-receptor binding site. It is validated in depth according to FDA quality standards, to ensure the ELISA reliability.
WorldHeartDay is celebrated to draw attention to heart illness and the range of associated health issues. The day aims to promote different preventative steps and changes in lifestyle to avoid any cardiovascular diseases, like heart attack, stroke, heart failure and any other condition related to the same.
On average, more than 17 million people die from heart-related illnesses every year.
Biomedica offers a range of biomarker assays for the early detection of heart disease https://lnkd.in/euWE-gc including tests for the detection of natriuretic peptides, which have proven to be powerful diagnostic and prognostic biomarkers of heart disease https://lnkd.in/eGnun-N.
Did you know that levels of NT-proANP might affect metabolic syndrome (MetS) differently in men and women?
Atrial natriuretic peptide (ANP) plays a key role in human metabolism and cardiometabolic disorders. Metabolic syndrome (MetS), a combination of obesity with other disease states of homeostasis of fats, sugars and proteins in the body, increases the risk of developing cardiovascular diseases and diabetes. In a study by Guo et al. NT-proANP had a protective effect against MetS in men. Men with high levels of NT-proANP had 0.60 times the risk of having MetS compared with men with low levels of NT-proANP. By contrast, women in the upper NT-proANP quartile group had 1.10 times the risk of having MetS compared to the lower quartile group. This suggests that NT-proANP may affect MetS differently in men and women.
Learn more at: Gender difference of association between plasma N-terminal pro-atrial natriuretic peptide and metabolic syndrome https://bit.ly/2RsHeCy
And check out the Biomedica NT-proANP ELISA:
• CE marked – for IVD use in the EU
• Small sample volume – 10 µl / well
• Assay suitable for rat/mouse samples – NT-proANP as a cardiovascular safety biomarker in rats